Below is a selected list of timely federal funding opportunities that are relevant to the osteopathic medical education community. AACOM updates this resource frequently.  Please bookmark the page for your reference. For a comprehensive listing of federal funding opportunities, please visit   

Featured Opportunities

July 22 - August 2

Health Resources and Services Administration

Radiation Exposure Screening and Education Program

Application Due: October 28, 2019

This grant is from the Radiation Exposure Screening and Education Program (RESEP) and was developed to inform and educate the public about services offered through the RESEP program; disseminate information on radiogenic diseases and the importance of early detection; screen eligible individuals for cancer and other radiogenic diseases; provide appropriate referrals for medical treatment; and facilitate putative applicants in the documentation of Radiation Exposure Compensation Act (RECA) claims.

Rural Health Network Development Planning Program

Letter of Intent: September 30, 2019

Application Deadline: November 29, 2019

This funding is under the Rural Health Network Development Planning Program (“Network Planning”). The purpose of the Network Planning program is to assist in the development of an integrated health care network, specifically with network participants who do not have a history of formal collaborative efforts. Network Planning goals are: (i) to achieve efficiencies; (ii) to expand access to, coordinate, and improve the quality of essential health care services; and (iii) to strengthen the rural health care system.

National Institutes of Health

(Re)Building a Kidney (UC2 Clinical Trial Not Allowed)

Letter of Intent: October 7, 2019

Application Due: November 7, 2019

This grant opportunity invites new applications for the (Re)Building a Kidney (RBK) Consortium. The goal of the RBK is to improve or restore failing kidney function after injury or disease. This FOA invites teams of investigators with complementary expertise to develop and test novel ways to either (1) stimulate productive kidney repair/regeneration in vivo, or (2) generate functional kidney tissue ex vivo for transplantation.

Microbiome and Aging: Impact on Health and Disease (R01 Clinical Trial Not Allowed)

Application Due: October 30, 2019

This opportunity invites projects focused on defining the factors that influence microbiome composition and functional characteristics during aging, understanding how the aging microbiome relates to the causes and pathophysiology of age-related chronic diseases, and development and testing of targeted interventions through diet, drugs, or live organisms.

Preclinical Screening for Natural Product Drug Interactions (Clinical Trial Not Allowed, R21)

Letter of Intent: October 1, 2019

Application Due: November 1, 2019

This grant seeks to identify natural products with the potential to inhibit or induce Phase I and Phase II drug metabolizing enzymes and drug transporters, thereby possibly contributing to pharmacokinetic interactions with other medications. These in vitro studies may include screening libraries of complex extracts and/or purified natural products in suitable medium to high throughput assays to identify potential interactions. They may also include isolation and identification of novel, or not commercially available, natural products within complex mixtures that exhibit pharmacokinetic interactions.

Polycystic Kidney Disease (PKD) Research and Translation Core Centers (U54 Clinical Trial Not Allowed)

Letter of Intent: October 21, 2019

Application Due: November 21, 2019

This Funding Opportunity Announcement (FOA) requests applications for Polycystic Kidney Disease (PKD) Research and Translation Core Centers (RTCC). The RTCCs are expected to work collaboratively with the Central Coordinating Site (CCS) as part of a PKD Research Consortium and serve as a national resource for the larger research community. The RTCCs should develop and share research resources (e.g. reagents, tools etc.), services and expertise that would be difficult or impractical to support in individual labs.

Participant Engagement and Cancer Genome Sequencing (PE-CGS): Research Centers (U2C Clinical Trial Optional)

Letter of Intent: September 30, 2019

Application Due: October 30, 2019

This grant is associated with the Beau Biden Cancer MoonshotSMInitiative that is intended to accelerate cancer research. Specifically, this FOA falls under a scientific priority designated by the Blue Ribbon Panel (BRP) as Recommendation A "Establish a Network for Direct Patient Engagement".

Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)

Letter of Intent: August 30, 2019

Application Due: September 30, 2019

The grant is to support collaborative research projects designed to address adverse sequelae of cancer therapies that persist and become chronic comorbidities or develop as delayed posttreatment effects. This grant supports basic, translational, and clinical research projects that seek to identify the mechanisms of therapy-induced adverse sequelae, clinically characterize the adverse sequelae, or translate the mechanistic understanding into therapeutic approaches to prevent or minimize the development of long-term sequelae.

July 8 - July 19

National Institutes of Health

Molecular Mechanisms of Blood-Brain Barrier Function and Dysfunction in Alzheimer's disease and Alzheimer's related dementias (AD/ADRD) (R01 Clinical Trial Not Allowed)

Letter of Intent: September 9, 2019

Application Due: October 9, 2019

The goal of this initiative is to elucidate the mechanistic links between blood brain barrier (BBB) dysfunction, Alzheimer’s Disease (AD) and AD-Related Dementias (ADRD), and how related comorbidities impact the basic molecular mechanisms of BBB health and function.

Discovery of Biomarkers and Biomarker Signatures for Neurological and Neuromuscular Disorders (R61/R33 Clinical Trial Optional)

Letter of Intent: August 4, 2019

Application Due: September 4, 2019

The purpose of this grant is to promote the discovery and/or early evaluation of strong candidate biomarkers and biomarker signatures that can be used as tools to facilitate the clinical development of neurotherapeutics and their use in clinical practice. Specifically, the focus of this grant is on the identification and initial biological, analytical and clinical evaluation of biomarkers and biomarker signatures for neurological and neuromuscular disorders.

Mechanisms of Tolerance (R21/R33 - Clinical Trial Required)

Application Due: October 16, 2019

This grant focuses on sensitivity and tolerance mechanisms underlying the development of alcohol use disorder. The intent of this opportunity is to: (1) develop hypotheses about cellular, molecular or network mechanisms that regulate sensitivity and tolerance to alcohol, and (2) develop quantitative models to predict the development of tolerance and the progression to alcohol use disorder.

Health Resources and Services Administration

Early Hearing Detection and Intervention Program

Application Deadline: November 8, 2019

The purpose of this program is to support comprehensive and coordinated state and territory systems of care so families with newborns, infants, and young children up to 3 years of age who are deaf or hard-of-hearing receive appropriate and timely services that include hearing screening diagnosis, and early intervention.

The NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00)

Application Due: December 4, 2019

The purpose of the NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00) is to encourage and retain outstanding graduate students recognized by their institutions for their high potential and strong interest in pursuing careers as independent cancer researchers. The award will facilitate the transition of talented graduate students into successful cancer research postdoctoral appointments and provide opportunities for career development activities relevant to their long-term career goals of becoming independent cancer researchers.